RNS Number : 1164L
ValiRx PLC
03 June 2025

3 June 2025

ValiRx PLC
("ValiRx" or the "Company")

New Evaluation and Material Transfer Agreement

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that its majority owned subsidiary, Cytolytix Ltd. ("Cytolytix") and Omios Biologics ("Omios"), a California based corporation, have entered into an Evaluation and Material Transfer agreement to evaluate the ability of Cytolytix's CLX001 oncolytic peptide technology to enhance activity of Omios's next-generation oncolytic virus immunotherapies (the "Agreement").

The Agreement focuses on incorporating Cytolytix's Oncolytic Peptide technology into the Omios next-generation Oncolytic Virus platform and is expected to take up to 12 months, for a nominal upfront payment. On conclusion of the evaluation, Omios has an option to enter into anOncolytic Peptide License Agreement to continue using Cytolytix technology. This signifies an exciting new opportunity for ValiRx and Cytolytix to further expand its portfolio and commercialise its portfolio of innovative cancer therapeutics.

Mark Eccleston, CEO of ValiRx commented *"We are pleased to announce this first Cytolytix commercial evaluation with Omios Bio and we see great synergy with their virus platform with a built-in biomarker for tumour targeting. We are very excited to work with Omios on the next generation of oncolytic virus leveraging Cytolytix's oncolytic peptide technology to enhance activity. Omios's innovative approach to enhancing their viruses' ability to selectively target and destroy cancer cells offers great synergy with our oncolytic peptide technology."*

Aldo Pourceht, CEO of Omios Biologics commented*"Our agreement with Cytolytix marks a significant strategic advancement for Omios. We look forward to evaluating how Cytolytix's oncolytic peptides can maximize the therapeutic impact of our next-generation VACV therapies. This collaboration is perfectly aligned with our core strategy: to build a leading oncolytic immunotherapy and tumor-targeted gene delivery platform, and most importantly, to rapidly advance our transformative cancer treatments into the clinic, for patients with challenging solid tumors."*

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here:https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub	https://valirx.com/link/Ve9mNe
ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 115 784 0026** www.valirx.com Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**

Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** www.vformation.biz lucy@vformation.biz sue@vformation.biz

Subscribe to our news alert service:https://valirx.com/s/f298d1

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit:www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRDDGDLGBGDGUD